Merck's Q3 Growth Came With a $550 Million Timing Benefit

Merck's third-quarter sales reached $18.09 billion, up 5% from a year earlier and 4% excluding currency. The result was strong enough for management to narrow its 2026 sales outlook and raise the midpoint, but one detail matters: product-purchase timing added about $550 million to pharmaceutical growth during the quarter.

That timing benefit does not erase the underlying product momentum, but it makes the headline growth rate look cleaner than the operating picture. Keytruda and its subcutaneous Qlex formulation generated $8.60 billion, up 6%, including $830 million from Qlex. Merck said earlier-stage cancer indications and metastatic uses drove demand. In the United States, unfavorable wholesaler purchase timing was largely offset by increased channel inventory, another reminder that shipments and end demand do not always move together in one quarter.

Winrevair provided the clearest new growth engine. Sales of the pulmonary arterial hypertension drug nearly doubled to $694 million as demand increased in the United States and launches progressed in Europe and Japan. Gardasil and Gardasil 9 rose 14% to $2.00 billion, helped by U.S. public-sector purchasing and pricing. Animal Health sales increased 4% to $1.68 billion.

The portfolio also showed where patent pressure is biting. Januvia and Janumet sales fell 39% to $380 million after U.S. generic competition followed loss of exclusivity. Bridion dropped 67% to $144 million for the same reason, while Lagevrio sales declined 88% to $17 million as Japanese demand weakened. Growth from newer products is increasingly important because these declines are structural, not simply quarterly noise.

Earnings did not rise with revenue. GAAP net income fell 12% to $5.07 billion, and GAAP diluted earnings per share declined to $2.04 from $2.32. Adjusted earnings per share fell 3% to $2.49. Both measures included a $0.12-per-share charge tied to a $400 million global license agreement with SciBrunch. GAAP gross margin also narrowed to 72.9% from 77.7% because of higher intangible-asset amortization, restructuring and production costs. Research and development expense rose 7% to $4.54 billion as Merck spent more on clinical programs and recorded the SciBrunch charge.

Management now expects 2026 sales of $66.8 billion to $67.3 billion, versus the prior range of $66.3 billion to $67.3 billion. It also raised the adjusted earnings forecast to $2.77 to $2.82 a share from $2.66 to $2.76. That comparison needs care. The new range includes one-time charges totaling $9.0 billion for Cidara, $5.7 billion for Terns and $400 million for SciBrunch, equal to $6.05 per share in aggregate. Merck reported adjusted earnings of $8.98 a share in 2025, when business-development charges reduced the result by only $0.20.

The pipeline helps explain why Merck is accepting those near-term charges. Phase 3 data showed sacituzumab tirumotecan reduced the risk of death by 32% versus chemotherapy in certain previously treated endometrial cancers. In a separate melanoma study with Moderna, intismeran plus Keytruda reduced the risk of recurrence or death by 42% compared with Keytruda alone. Those are meaningful clinical signals, but approvals, commercialization and eventual revenue still require further execution.

For investors, the quarter shows both sides of Merck's transition. Keytruda remains enormous, Winrevair is scaling quickly and the late-stage pipeline is producing important results. Yet purchase timing, generic erosion and unusually large transaction charges complicate any simple reading of the raised outlook.